Updated Date: Tue, 21 Feb 2023 00:00:00 EST

Updated Date: Tue, 21 Feb 2023 00:00:00 EST

Updated Date: Tue, 21 Feb 2023 00:00:00 EST

Updated Date: Tue, 21 Feb 2023 00:00:00 EST

Phase 2 study of OK-101 will commence soon as company hopes drug will provide unmet need

Research into modified RNA messages could help treat diseases and develop new therapies

Tech was created to overcome adoption obstacles currently reducing the use of predictive human liver models

If approved company’s prostate cancer therapy will be the first dual-action tablet available in EU

Updated Date: Fri, 17 Feb 2023 00:00:00 EST

Updated Date: Fri, 17 Feb 2023 00:00:00 EST